Results 21 to 30 of about 35,970 (259)

Long-term neuropsychological outcomes in children with febrile infection-related epilepsy syndrome (FIRES) treated with anakinra

Frontiers in Neurology, 2023
Background Febrile-infection related epilepsy syndrome (FIRES) is a rare epilepsy syndrome in which a previously healthy individual develops refractory status epilepticus in the setting of a preceding febrile illness.
A. Shrestha, E. Wood, Gretchen Berrios-Siervo, Coral M. Stredny, K. Boyer, Clemente Vega, S. Nangia, E. Muscal, K. Eschbach   +8 more
semanticscholar   +1 more source

Impact of anakinra use on clinical outcomes in children with moderate or severe multisystem inflammatory syndrome in children: a propensity score matched retrospective cohort study

Pediatric Rheumatology Online Journal, 2023
Background The treatment of children with multisystem inflammatory syndrome in children (MIS-C) related to SARS-CoV-2 infection involves immunomodulatory therapies such as IVIG and steroids.
Esra B. Akkoyun, Zachary Most, Harita Katragadda, Andrew Yu, Lorien Nassi, Nicole Oakman, Sarah Ginsburg, Mia Maamari   +7 more
doaj   +1 more source

Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19

JAMA Network Open, 2023
Key Points Question Is the use of anakinra plus the standard of care effective compared with the standard of care alone in reducing the probability of requiring mechanical ventilation among patients with severe COVID-19 pneumonia?
P. Fanlo, B. Gracia-Tello, Eva Fonseca Aizpuru, Jorge Álvarez-Troncoso, A. González, S. Prieto-González, M. Freire, A. Argibay, L. Pallarés, J. Todolí, Mercedes Pérez, S. Buján-Rivas, B. Ibáñez   +12 more
semanticscholar   +1 more source

OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO)

Journal of Crohn's & Colitis, 2023
Acute severe ulcerative colitis (ASUC) is a severe manifestation of ulcerative colitis (UC) that requires hospitalisation. Despite significant advances in therapeutic options for UC and in the medical management of steroid-refractory ASUC, the ...
T. Raine, S. Vaja, S. Subramanian, B. Brezina, C. Probert, A. Steel, M. Lofthouse, R. Speight, C. Lamb, S. Sebastian, J. Kane, J. Thut, S. Din, I. Arnott, L. Smith, J. Galea, P. Hendy, L. Flores, C. Selinger, F. Onoviran, H. Steed, M. Green, J. Williams, V. Jairath, W. Qian, H. Pavey, K. Champion, F. Dowling, M. Thomas, K. Wolf, C. Davis-Wilkie, M. Parkes, A. Kaser   +32 more
semanticscholar   +1 more source

Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background ST‐segment–elevation myocardial infarction is associated with an intense acute inflammatory response and risk of heart failure. We tested whether interleukin‐1 blockade with anakinra significantly reduced the area under the curve for hsCRP ...
Antonio Abbate, Cory R. Trankle, Leo F. Buckley, Michael J. Lipinski, Darryn Appleton, Dinesh Kadariya, Justin M. Canada, Salvatore Carbone, Charlotte S. Roberts, Nayef Abouzaki, Ryan Melchior, Sanah Christopher, Jeremy Turlington, George Mueller, James Garnett, Christopher Thomas, Roshanak Markley, George F. Wohlford, Laura Puckett, Horacio Medina de Chazal, Juan G. Chiabrando, Edoardo Bressi, Marco Giuseppe Del Buono, Aaron Schatz, Chau Vo, Dave L. Dixon, Giuseppe G. Biondi‐Zoccai, Michael C. Kontos, Benjamin W. Van Tassell   +28 more
doaj   +1 more source

Anakinra treatment for refractory cerebral autoinflammatory responses

Annals of Clinical and Translational Neurology, 2022
Refractory cerebral autoinflammatory–autoimmune diseases are often associated with dysregulated innate immunity and are targeted by anakinra, an interleukin‐1 receptor antagonist.
Yoonhyuk Jang, Woo‐Jin Lee, Han Sang Lee, Kon Chu, Sang Kun Lee, Soon‐Tae Lee   +5 more
doaj   +1 more source

Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature

Frontiers in Medicine, 2023
Background Gout is the most common type of inflammatory arthritis. Nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine are the first-line agents, although they are contraindicated in many patients.
Sicylle Jeria-Navarro, A. Gómez-Gómez, Hyesang Park, E. Calvo-Aranda, H. Corominas, M. Pou, C. Díaz-Torné   +6 more
semanticscholar   +1 more source

Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study.

PLoS ONE, 2023
BackgroundIn patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels ≥ 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death.
Francesco Vladimiro Segala, Emanuele Rando, Federica Salvati, Marcantonio Negri, Francesca Catania, Flavia Sanmartin, Rita Murri, Evangelos J Giamarellos-Bourboulis, Massimo Fantoni   +8 more
doaj   +1 more source

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

Hepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr, Benedikt Kaufmann, Maria Eugenia Inzaugarat, Theresa Maria Holtmann, Lukas Geisler, Jana Hundertmark, Marlene Sophia Kohlhepp, Laela M. Boosheri, Daisy R. Chilin‐Fuentes, Amanda Birmingham, Kathleen M. Fisch, Joel D. Schilling, Sven H. Loosen, Christian Trautwein, Christoph Roderburg, Münevver Demir, Frank Tacke, Hal M. Hoffman, Ariel E. Feldstein, Alexander Wree   +19 more
wiley   +1 more source

Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) [PDF]

, 2017
Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of con-firmed HF cases in the United States. However, there are no highly effective evidence-basedtreatments currently available for these patients.
Abbate, Antonio, Abouzaki, Nayef, Arena, Ross, Biondi-zoccai, Giuseppe, Buckley, Leo F., Canada, Justin M., Carbone, Salvatore, Dixon, Dave L., Oddi-erdle, Claudia, Trankle, Cory R., Van Tassell, Benjamin W.   +10 more
core   +1 more source